Cell therapies have suffered from hyped-up expectations, clinical setbacks and high costs. But maybe, just maybe, Arovella is ...

The S&P/ASX 200 fell 3% in December as Santa rally failed to eventuate yet again. But… it wasn't ALL bad, as these 50 stocks ...

ASX tech rocked a 50pc gain in 2024, Archer Materials shone in December, and Dubber and Brainchip have cashed in on major ...

Ads for AI-related roles are shrinking in Australia, new job data reveals, with the number down 35 per cent compared to over ...

Neurizon recently received EMA orphan designation for NUZ-001 to treat ALS and filed an FDA IND application to begin a phase ...

Aussies are missing out on hundreds of thousands of dollars in superannuation returns, according to one of the nation’s largest super funds.

Gold outshined the chasing pack as only a handful of commodities sailed through choppy economic waters unscathed in a ...

Morningstar’s analyst picks ResMed and PWR as top ASX long-term plays, with ResMed eyeing sleep market domination.

With pending news flow of significance coming in 2025, these ASX-listed gas companies could be worth putting on your radar.

Percheron Therapeutics' board of directors has written a letter to shareholders following failure of its phase 2b trial.

Summit Minerals led resource gainers after signing a deal to acquire the Mundo Novo niobium and rare earths project in central Brazil.